EFFECT OF CROSSLINKING AGENT ON DEVELOPMENT OF GASTRORETENTIVE MUCOADHESIVE MICROSPHERES OF RISEDRONATE SODIUMâ€ by Gedam, Shweta et al.
Original Article 
 “EFFECT OF CROSSLINKING AGENT ON DEVELOPMENT OF GASTRORETENTIVE 
MUCOADHESIVE MICROSPHERES OF RISEDRONATE SODIUM” 
 
SHWETA GEDAM*, PRITEE JADHAV, SWATI TALELE, ANIL JADHAV 
Sandip Institute of Pharmaceutical Sciences, Mahiravani, Nashik 422213, M. S., India 
Email: shwetashahare16@gmail.com  
Received: 19 Mar 2018, Revised and Accepted: 06 Jun 2018 
ABSTRACT 
Objective: The present investigation was undertaken to develop and evaluate a gastroretentive mucoadhesive microspheres of anti-osteoporosis 
drug risedronate sodium to enhance the residence time and drug release by studying the effect of the crosslinking agent to obtain the best 
formulation with reduced particle size and good in vitro mucoadhesion strength. 
Methods: Selected drug risedronate sodium is a potent pyridinyl bisphosphonate used for the treatment of osteoporosis, and other bone disorders. 
Microspheres using sodium alginate as a polymer and calcium chloride solution as a cross-linker were prepared successfully by the emulsification 
crosslinking method. The 23 factorial design was used to study the effects of various variables like a drug: polymer ratio, crosslinking agent 
concentration and crosslinking time on the particle size and in vitro mucoadhesion strength. All these formulations were evaluated for entrapment 
efficiency, percentage yield and cumulative drug release. F1 batch was selected as best formulation and evaluated for scanning electron microscopy, 
fourier transforms infrared spectroscopy, differential scanning calorimetry, stability study. 
Results: Design batches were evaluated for percent yield (61.29-89.33%), % entrapment efficiency (42.25±0.620-62.58±0.330), mucoadhesion 
strength (68.15±0.37-82.24±0.72%) and drug release at 12 h (67-84%). Among the microspheres formulation, an F1 batch of (0.5:1) drug: polymer 
concentration and at 4% concentration of calcium chloride as a crosslinker was considered best formulation with reduced particle size 
32.85±0.774μm, % intro mucoadhesion. 82.24±0.72. In vitro mucoadhesion strength was increased with the increasing crosslinking time from 5 min 
to 10 min. The fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) study showed no interaction between 
drug and polymer. X-ray diffraction (XRD) spectrum of microspheres indicates that drug particles are dispersed at the molecular level in the 
polymer matrices so no indication of the crystalline nature of the drug nature. Scanning electron microscopic (SEM) study showed that 
microspheres were spherical in shape with a smooth surface. F1 batch shows percentage cumulative drug release 84.07%. In vitro dissolution 
studies indicates that percent cumulative drug release from microspheres follows zero order kinetics plot which indicates controlled-release drug-
delivery for 12 h which leads to control of plasma concentration. 
Conclusion: The results show that the formulation that contains (0.5:1) drug: polymer ratio, calcium chloride in 4% concentration and crosslinking 
time 10 min is the best one and can be utilized to formulate risedronate sodium mucoadhesive microspheres to enhance gastric residence time, 
improved patient compliance and reduction in the frequency of drug administration.  
Keywords: Risedronate sodium, Gastro retentive drug delivery system (GRDDS), Emulsification crosslinking method, % in vitro mucoadhesion 




Oral formulations have earned a significant place among the various 
dosage forms developed for human administration. In most of the 
cases, the conventional oral delivery systems show limited 
bioavailability because of fast gastric-emptying time among many 
other reasons involved [1, 2]. However, the recent technological 
development has resulted in many novel pharmaceutical products, 
mainly the controlled release drug delivery systems to overcome 
this problem. Gastro-retentive drug delivery system (GRDDS) is one 
such example where the attribute like gastric retention time coupled 
with the drug release for an extended time has significantly 
improved patient compliance. Some inherent limitations of the 
conventional oral drug delivery systems have ignited the interest to 
this new delivery system. Fast gastric emptying is associated with 
conventional oral medications leads to a bioavailability issue for 
many drug molecules [3]. 
Micro carrier’s technology offers a novel approach for drug delivery 
by coupling the drug to microcarrier particles which modify the 
release and absorption characteristics of the drug. Microspheres 
possess important features, among the particulate drug delivery 
systems by virtue of their small size and efficient carrier 
characteristics; however, the success of the microspheres delivery 
system is limited due to their short residence time at the site of 
absorption. It would, therefore, be advantageous to have the means 
for providing an intimate contact of the microspheres delivery 
system with absorbing biological membranes. This can be 
accomplished by coupling mucoadhesion characteristics to 
microspheres by using mucoadhesive polymer and developing 
mucoadhesive microspheres [4]. Mucoadhesive microspheres as 
modified release formulations maintain the blood levels of the active 
ingredients for a prolonged period of time and reduces the 
frequency of drug administration and improve the patient 
compliance [5, 6].  
Risedronate is a potent pyridinyl bisphosphonate used for the 
treatment of osteoporosis, Paget’s disease and other bone 
disorders. Risedronate has a high affinity for hydroxyapatite 
crystals in bone and is a potent antiresorptive agent. At the 
cellular level, risedronate inhibits osteoclasts. The osteoclasts 
adhere normally to the bone surface but show evidence of reduced 
active resorption. The main reason for lack of therapeutic 
effectiveness is low oral bioavailability (0.63%). The low oral 
bioavailability of the drug can be attributed to its complexion 
nature with metal ions and site-specific absorption (upper GIT). 
The plasma half-life of the drug is ~1.5 h. Absorption after an oral 
dose is relatively rapid (Tmax~1 hr) and occurs throughout the 
upper GIT. The site-specific absorption (upper GIT) of risedronate 
sodium provides a strong rationale for its use as a model drug for 
gastroretentive dosage form [7]. 
The aim of the study was to prepare as mucoadhesive microspheres 
to reduce dosing frequency and to effectively reduce variations in 
plasma drug concentration by delivering the drug in a controlled and 
reproducible fashion.  
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MATERIALS AND METHODS 
Materials 
Risedronate sodium was obtained as a generous gift sample from 
JPN pharmaceutical Ltd. (Central Mumbai, India). Sodium alginate, n-
octanol, calcium chloride and span 80 were purchased from 
Research-lab fine Chem industries. All other chemicals and reagents 
used were of analytical reagent grade and were procured from 
commercial sources. 
Preparation of microspheres of risedronate sodium 
The emulsification crosslinking method is used to prepare microspheres 
of risedronate sodium using calcium chloride as a crosslinking agent. In 
brief, risedronate sodium was dispersed in an aqueous solution 
containing 3%, w/v sodium alginate. The solution was dispersed in n-
octanol containing 2%, v/v span 80 using a mechanical stirrer (Remi, 
RQ127A/D) at 1800rpm. The ratio of the aqueous to n-octanol phase 
used was 1:20. The resultant w/o emulsion was stirred for 30 min. This 
was followed by the dropwise addition of the 4%, w/v calcium chloride 
solution under mechanical agitation of different speeds using homo 
dispensers for another 5 min. The microspheres were collected by 
vacuum filtration, washed three times with isopropyl alcohol and dried 
in an air at room temperature [8]. 
The batches were prepared according to the formulation design 
(table 3). 
Optimization 
The optimization of pharmaceutical formulations with regard to one 
or more attribute has always been a subject of importance and 
attention for those engaged in formulation research. The objective is 
to produce a mathematical model that describes the responses. In 
general, the procedure consists of preparing a series of formulations, 
varying the concentrations of the formulation ingredients in some 
systematic manner (Bolton, 2004). The various computations for the 
current optimization study were performed using Design Expert® 
software (Design Expert trial version 7.0.0; State-Ease Inc., 
Minneapolis, MN, USA). A three-factor two-level full factorial design 
was used for the systemic study of combination of Polymers. 
23 full factorial design  
If three factors A, B, and C, each at two levels, are to be investigated, 
eight trials are necessary for a full factorial design, as shown in 
(table 3). This is also called a 23 experiment, three factors, each at 
two levels. A 23full factorial design was constructed where the 
polymer, inlet temperature, aspirator rate was selected as factors. 
The levels of these factors were selected on the basis of initial 
studies and observations. All the other formulation aspects and 
processing variables were kept invariant throughout the study 
period. Polynomial models including interaction and quadratic 
terms were generated for the entire response variables using 
multiple linear regression analysis (MLRA) approach. The 
polynomial equations can be used to draw a conclusion after 
considering the magnitude coefficient and the mathematical sign 
that the coefficient carries. A high positive or negative value in the 
equation represents that by making a minor change in the setting of 
that factor one may obtain a significant change in the dependent 
variable.  
The statistical validity of the polynomials was established on the 
basis of analysis of variance (ANOVA) provision in the Design Expert 
software. Level of significance was considered at p<0.05. The best-
fitting mathematical model was selected based on the comparison of 
several statistical parameters, including the coefficient of variation 
(CV), the multiple correlation coefficients (R2), the adjusted multiple 
correlation coefficient (adjusted R2), and the predicted residual sum 
of squares (PRESS), provided by the software. PRESS indicates how 
well the model fits the data, and for the chosen model, it should be 
small relative to the other models under consideration. The 3-D 
response surface graphs and the 2-D contour plots were also 
generated by the Design Expert® software (8.0.4.). These plots are 
very useful to see interaction effects of the factors on responses.  
Data analysis of factorial design 
Once the experimental design is applied and the observations are 
made then the analysis of the data obtained is carried out by one of 
the two methods;  
Polynomial Equation: It is the most common technique for 
quantitative factor analysis. The first step is to transform real values, 
i.e. to obtain coded values. The equation is carried out using 
transformed values and is given by 
Y= ᵝ0+ᵝ1X1+ᵝ2X2ᵝ3X3+ᵝ12X1X2+ᵝ13X1X3+ᵝ23X2X3+ᵝ23X1X2X3+…. 
Where Y is the measured response, Xi is the level (e. g. Drug: 
polymer weight ratio, the concentration of calcium chloride, cross 
linking time) of the ith factor, ᵝ0 is the intercept ᵝ1, ᵝ2, ᵝ3, ᵝ12, ᵝ23and 
ᵝ123 are regression coefficient for the variables and interaction 
between the variables. 
 
Table 1: Investigating ranges of variables for risedronate sodium and sodium alginate microspheres 
S. No. Low level High level 
X1 0.5:1 1:1 
X2 2 4 
X3 5 10 
 
Table 2: Layout of 23 full factorial design 
Variable F1 F2 F3 F4 F5 F6 F7 F8 
X1 -1 1 1 -1 1 -1 -1 1 
X2 1 1 1 -1 -1 -1 1 -1 
X3 1 1 -1 1 1 -1 -1 -1 
 
Table 3: Formulation for risedronate sodium microspheres 
Formulation X1 X2 X3 
F1 0.5:1 4 10 
F2 1:1 4 10 
F3 1:1 4 5 
F4 0.5:1 2 10 
F5 1:1 2 10 
F6 0.5:1 2 5 
F7 0.5:1 4 5 
F8 1:1 2 5 
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Formulation of Microspheres as per 23 factorial design 
Independent variables: X1 = Drug: Polymer weight ratio (mg)  
X2 = Concentration of CaCl2 (%) 
X3 = Cross-linking time (min) 
Dependent variables: Y1 = Particle size (micron) 
Y2 = In vitro mucoadhesion (%) 
Evaluation of prepared microspheres 
Percentage yield 
The percent yield of microsphere was calculated based on the 
amount of drug and polymer used for the formulation of 
microspheres [9]. The percentage yield was calculated from Eq. 1 
% Yield =
Total weight of microspheres
Theoretical weight of drug and polymer 
 X 100-----------(1) 
Entrapment efficiency 
50 mg equivalent of risedronate sodium containing microspheres 
was dissolved in 10 ml of water. The absorbance was measured by a 
UV spectrophotometer (Agilent, carry 60UV-Vis) at 224 nm [10]. The 
% entrapment efficiency was calculated from Eq. 2 
% Entrapment Efficiency =
practical amount of drug 
Theoretical amount
X 100-----------(2) 
The results were analyzed in triplicate and standard deviations are 
reported. 
Particle size analysis 
Particle size analysis of risedronate sodium was determined by an 
optical microscope. A little amount of dry microspheres was 
dispersed in cyclohexane (5cc) (cyclohexane was selected due to 
insolubility of polymer and drug in it). Then the suspension was 
sonicated for 5s. A small drop of the suspension, thus obtained was 
placed on a clean glass slide. The slide containing sodium alginate 
microspheres was mounted on the stage of the microscope, and the 
diameter of molecules was evaluated utilizing a calibrated ocular 
micrometre. The particle size analysis was carried out using a 
microscopic image analysis technique [11]. 
The results were analyzed in triplicate and standard deviations are 
reported. 
Particle shape and surface morphology 
The morphology of the prepared microspheres was investigated by 
scanning electron microscopy (Diya labs, New Mumbai). The 
microspheres were fixed on adequate supports and coated with gold 
under an argon atmosphere using a gold sputter module in a high-
vacuum evaporator. Observations under different magnifications 
were performed at 15 kV [9, 10]. 
In vitro drug release study 
The drug release rate from mucoadhesive microspheres was carried out 
using USP dissolution apparatus I (ED2L Electrolab). A weight of 
mucoadhesive microspheres corresponding to 58 mg drug was filled 
into a capsule and placed in the basket. Dissolution media was 900 ml of 
0.1N HCl maintained at 37±0.5˚C and stirred at 100 RPM. 5 ml sample 
was withdrawn at suitable time intervals for 12 h and 5 ml fresh 
dissolution medium was replaced after each withdrawal. These samples 
were analyzed for the drug spectrophotometrically at 224.5 nm [10]. 
In vitro mucoadhesive strength 
A freshly cut 2 cm piece of goat stomach mucosa was obtained and 
cleaned by washing with an isotonic saline solution. One hundred 
milligrams of microspheres were placed on the mucosal surface was 
fixed over polyethene support. The microspheres were brought in 
contact with simulated electrolytes (SNES: an aqueous solution 
containing 8.77 mg/ml NaCl, 2.98 mg/ml KCl and 0.59 mg/ml CaCl2 
per liter). The goat stomach mucosa was washed with phosphate 
buffer (pH 6.6) at the rate of 5 ml/min using a peristaltic pump. Sixty 
minutes after application of microspheres, the concentration of drug 
in collected perfusate was determined spectrophotometrically. The 
amount of microspheres corresponding to the drug amount in 
perfusate was calculated. The amount of adhered microspheres was 
estimated from the difference between the applied microspheres 
amount and the amount of flowed microspheres [12]. The percent 
mucoadhesion was calculated from Eq. 3 
% Mucoadhesion =
Amount of drug in washout liquid
Amount of drug in applied microsphere
x 100-----------(3) 
The results were analyzed in triplicate and standard deviations are 
reported. 
RESULTS AND DISCUSSION  
Preparation of microspheres 
Eight batches were prepared by the emulsification crosslinking method 
as per factorial design, in which Drug: Polymer weight ratio (mg) (X1), 
Concentration of CaCl2 (%) (X2), Cross-linking time (min) (X3), were 
selected as independent variables and (micron) particle size (Y1), %In 
vitro mucoadhesion (Y2) of the microspheres were taken as the 
dependent variables were treated using design expert software. 
Percentage Yield 
The percentage yield of different batches was determined by 
weighing the microspheres after drying. The percentage yields of 
different formulations were found to be in the range of 61.29 % to 
89.33 %. This high yield of production is may be due to all the 
polymer is available for gelation into a cross linking agent. 
Entrapment efficiency 
The drug entrapment efficiency of different batches of microspheres 
was found in the range of 36.05 % to 62.58 %. The maximum 
percent of drug entrapment efficiency was found to be in the 
formulation batch F3. The % entrapment efficiency showed 
dependence on drug loading, the amount of cross-linking agent and 
time of cross-linking. The formulations loaded with the higher 
amount of drug exhibited higher entrapment efficiencies. The 
entrapment efficiency, however, showed an inverse relationship 
with the increase in cross link density, which will reduce the free 
volume spaces within the polymer matrix and hence, a reduction in 
entrapment efficiency. 
Particle size analysis 
The particle size of microspheres varied somewhat among the 
formulation due to variation in the composition of formulations. 
Formulation F6 showed a relatively large size, i.e. 54.32 µm and 
formulation F1 showed relatively small size i.e. 32.85 µm. The (table 4) 
shows the mean particle size of various batches. Preliminary studies 
showed that as the concentration of polymer was increased, the 
particle size also proportionally increased. Low alginate 
concentrations (1%, w/v and 2%, w/v) resulted in clumping of 
microspheres, whereas high sodium alginate concentration (4%, 
w/v) resulted in the formation of discrete microspheres with size 90 
µm. This could be attributed to an increase in the relative viscosity at 
a higher concentration of polymer and the formation of larger 
particles during emulsification. Hence the optimized concentration 
of 3%, w/v was selected for preparing the different batches of the 
microspheres. The size of microspheres was increased with an 
increased with an increase drug loading. This can be attributed to 
the corresponding increase in viscosity of drug-polymer dispersion 
comprising the internal phase of the emulsion. A similar increase in 
the size of microspheres was also observed to increase in calcium 
chloride concentration as well as cross-linking time. The addition of 
a higher amount of Ca2+will result in relatively more cross-linking of 
the gluronic acid units of sodium alginate, thereby leading to the 
formation of larger microspheres. Similarly, increasing the cross 
linking time will increase the extent of cross-linking and thereby 
increase the particle size.  
Particle shape and surface morphology 
Morphological analysis of the risedronate sodium microsphere was 
carried out by optical microscopy. The microspheres were found to 
be discrete and spherical in shape. 
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Table 4: Trial batches evaluation 
Batch No. P. S.±SD* P. I. M.±SD* P. Y. P. E. E.±SD* 
F1 32.85±0.774 82.24±0.72 89.33 58.56±0.230 
F2 39.12±1.447 75.12±1.04 61.29 42.25±0.620 
F3 34.15±0.603 78.13±0.83 82.23 62.58±0.330 
F4 47.94±2.12 72.52±1.07 80.33 43.89±0.617 
F5 37.64±0.732 75.12±0.64 86.67 46.4±0.189 
F6 54.32±0.612 70.24±1.05 66.12 42.25±0.330 
F7 36.18±0.835 76.75±0.77 84.44 50.65±0.540 
F8 46.45±0.961 68.15±0.37 79.03 36.05±0.430 
*SD standard deviation, n=3, P. S.: particle size, P. I. M.: percent in vitro mucoadhesion, P. Y.: percent yield, P. E. E.: percent entrapment efficiency 
 
In vitro drug release 
To determine the release risedronate sodium is in a controlled manner 
by formulating the polymeric microspheres, in vitro drug dissolution 
studies were carried out in 0.1 N HCl solutions using USP dissolution 
apparatus I. F1 batch shows significant cumulative percent drug release 
from microspheres this may be due to smaller particle size, which leads 
to larger area of contact with the dissolution medium favour more rapid 
dissolution of the drug in comparison with larger particles. Drug release 
of all eight formulations is shown in fig. 1. 
  
 
Fig. 1: Graphical representation of comparative release profile of eight formulations [mean±SD, n=3] 
 
In vitro mucoadhesion study 
Mucoadhesion studies were followed to ensure the adhesion of the 
formulation to the stomach mucosa for a prolonged period of time 
at the site of absorption. The % In vitro mucoadhesion of all eight 
batches were found to be in the range of 68.15 0.37% to 
82.24+0.72%. Selected batch F1 shows higher percent in vitro 
mucoadhesion this may be due to sodium alginate is practically 
insoluble in aqueous acidic solution; whereas, its solubility, 
hydration and bioadhesion properties were increased in the 
simulated intestinal fluid due to ionization of the carboxyl acid 
group and other functional groups present in the polymer. This 
increased solubility allowed more solvent to penetrate the 
polymeric coat, producing a viscous gel and increasing the 
mucoadhesion property. 
Fourier transform infrared spectroscopy (FTIR) 
To check the compatibility of the drug with a polymer, infrared 
spectra of drug, polymers and mixture of drug-polymer were studied 
by using FTIR-ATR (spectrum 2, Perkin Elmer). The IR spectrum is 
shown in fig. 2. Indicates that there is no physicochemical 
interaction in between the drug and polymer which suggest that the 
polymer was compatible with FTIR spectra of risedronate sodium. 
  
   
(A) (B) (C) 
Fig. 2: Fourier transform infrared (FTIR) spectra of risedronate sodium (A), sodium alginate (B), risedronate sodium and polymer 
physical mixture (C) 
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Differential scanning calorimetric (DSC) study 
Differential scanning calorimetry (DSC) thermogram of risedronate 
sodium is shown in the fig. 3. Differential scanning calorimetric (DSC) 
studies indicate a sharp endothermic peak at 268.09˚C corresponding to 
the melting point of the sample which matches with the melting point of 
risedronate sodium indicating the purity of the drug. From the 
differential scanning calorimetric (DSC) overlay thermogram of pure 
drug and physical mixture with sodium alginate; it can be concluded that 
the occupants and drug don’t have any interaction with each other. Also 
the drug did not form a complex with the excipients as the endothermic 
peaks remained unchanged in position. 
 
   
(A) (B) (C) 
Fig. 3: Differential scanning calorimetry (DSC) curves of risedronate sodium (A), sodium alginate (B), curves of Microsphere formulation (C) 
 
Experimental design and data analysis  
The aim of the present work was to achieve optimized formulations for 
risedronate sodium microspheres by determining the effects of some 
important factors (variables) and their interactions during the process of 
preparation on microspheres physicochemical properties. Meanwhile, 
the microspheres were being processed; the impact of different factors 
had been evaluated by making changes in their quantity. Finally, three of 
the most significant factors had been chosen as the independent 
variables. According to a 23 factorial design and considering these three 
variables, an experimental matrix was performed by using design expert 




Half-Normal plot Pareto chart 
 
Analysis of variance and model equations 
In the next step, the significance of this influence was statistically 
confirmed by ANOVA Test. According to applied 23 experimental 
design, including 8 experiments were performed to optimize the 
formulation method of microspheres to get maximum entrapment 
efficiency in terms of response. The obtained results were entered in 
design expert software 8.0.4. and a model equation was obtained to 
get the fit result for particle size. The final model in terms of coded 
factors is, 
Particle Size =+41.08+5.88*A+0.099*B+2.57* C-2.43* B*C 
The model F-value of 9.30 implies the model is significant.  
Values of "Prob>F" less than 0.0500 indicates model terms are 
significant. In this case, A are significant model terms. 
  
   
(A) (B) (C) 
Fig. 4: (A): Predicted Vs. Actual values of particle size, (B): Contour plot shows the effect of concentration of calcium chloride (B) and 
cross-linking time (C) on the particle size, (C): 3D contour plot shows the effect of concentration of calcium chloride (B) and cross-linking 
time (C) on the particle size 
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In vitro mucoadhesion 
  
Half-normal plot Pareto chart 
 
Analysis of variance and model equations  
In the next step, the significance of this influence was statistically 
confirmed by ANOVA Test. According to applied 23 experimental 
design, including 8 experiments were performed to optimize the 
formulation method of microspheres to get maximum in vitro 
mucoadhesion in terms of response. The obtained results were 
entered in design expert software 8.0.4. and a model equation was 
obtained to get the fit result for in vitro mucoadhesion. The final 
model in terms of coded factors is, 
In vitro mucoadhesion =+74.49-3.71*A-0.57* B–2.51* C+1.11*B *C 
The model F-value of 45.13 implies the model is significant. Values of 
"Prob>F" less than 0.0500 indicates model terms are significant. In 
this case A, C and BC are significant model terms. Values greater than 
0.1000 indicates the model terms are significant. 
Optimized formulations 
F1 formulation was selected as optimized formulation on the basis of 




(A) (B) (C) 
Fig. 5: (A): Predicted Vs. actual values of in vitro mucoadhesion, (B): Contour plot shows the effect of concentration of calcium chloride (B) 
and cross-linking time (C) on the in vitro mucoadhesion, (C): 3D Contour plot shows the effect of concentration of calcium chloride (B) and 
cross-linking time (C) on the in vitro mucoadhesion 
 
Table 5: Predicted drug-loading and related obtained response from three of selected formulations 
Solution No. X1 X2 X3 Y1 Y2 








F1 0.5:1 4 10 32.85 30.11 82.24 82.39 
From the obtained data, formulations F1 is selected as optimized formula and formulated times to confirm the optimized formulation. The selected 
formulation F1 had has been chosen for particle size determination, entrapment efficiency and morphological evaluation by scanning electron 
microscopy (SEM), x-ray diffraction (XRD) and in vitro mucoadhesion study. 
 
Evaluation of optimized batch 
Table 6: Evaluation of optimized batch 
Solution P. E. E.±SD* P. S.±SD* P. C. D. R.±SD* 
F1 58.56±0.230 32.85±0.774 84.07 
*SD standard deviation, n=3, P. E. E.: Percent entrapment efficiency, P. S.: Particle size (µm), P. C. D. R.: Percent cumulative drug release 
 
SEM: Morphology of the optimized batch was F1 studied by SEM 
analysis. The fig. 6 shows images of the optimized batch. SEM 
was done in Diya labs, (Airoli, New Mumbai) by scanning 
electron microscope. Photograph of SEM for showing that the 
drug may be present in the bulk of the microspheres and not 
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Fig. 6: Scanning electron microscopy (SEM) image of optimized 
batch 
 
X-ray diffraction (X-RD) studies 
X-ray diffraction (XRD) analysis was carried by using x-ray 
diffraction (XRD) system. The x-ray diffraction (XRD) pattern for 
pure risedronate sodium and risedronate sodium loaded 
microspheres are shown in fig. 7, changes in the number of peaks 
and few diffuse peaks were observed in risedronate sodium loaded 
microspheres with reduced intensity to a greater extent as 
compared to x-ray diffraction (XRD) spectrum of pure drug, This 
indicates that drug particles are disperse at the molecular level in 
the polymer matrices so no indication of the crystalline nature of the 
drugs was observed in the drug loaded microspheres and it changes 
towards amorphous form. The increase in the amorphous nature of 




Fig. 7: X-ray diffraction (XRD) graph of risedronate sodium (A), x-ray diffraction (XRD) graph of microsphere formulations (B) 
 
Kinetic treatment to dissolution data 
  
Zero order kinetics plot First order kinetics plot 
  
Higuchi model plot Korsmeyer peppas plot 
Fig. 8: Kinetic treatment of dissolution data [mean±SD, n=3] 
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Effect of temperature and humidity 
Effect of temperature and humidity of the prepared microspheres was 
carried out, by storing optimized formulation at 4±2 ˚C, and at room 
temperature 45 % RH for 30 d in a stability chamber. Two parameters, 
namely residual entrapment efficiency and in vitro release studies 
were carried out. It is found that microspheres stored at room 
temperature are not stable, whereas stored at 4˚C is stable given in 
(table 7). Microspheres at room temperature showed decreases in the 
residual entrapment efficiency and different release pattern. 
 
Table 7: Effect of temperature and humidity on optimized batch 
Temperature condition Parameters Days 
 
4±2 °C 
 0 7 14 28 
Drug release (%) in 14th hrs 71.24 76.59 88.45 93.45 
 
ABBREVIATION  
GRDDS: Gastroretentive Drug Delivery System; EE: Entrapment 
Efficiency; HCL: Hydrochloric Acid; SEM: Scanning Electron 
Microscope; FTIR: Fourier Transform Infrared; UV: Ultraviolet; IR: 
Infrared; XRD: X-ray Diffraction; DSC: Differential Scanning 
Calorimetry 
CONCLUSION 
The mucoadhesive microspheres were formulated which aimed at 
an effective reduction in variation in plasma drug concentration by 
delivering the drug in a controlled and reproducible fashion of 
risedronate sodium, a potent pyridinyl bisphosphonate, used in the 
treatment of osteoporosis, and other bone disorders. Mucoadhesive 
microspheres are an attractive concept, in that the drug can be 
entrapped inside particles to be released at the mucosal surface, 
where the particles are sticking and enhances gastric residence time. 
SEM photographs showed that microspheres were almost spherical 
in shape with slight smooth surfaces. In vitro, mucoadhesive studies 
revealed that concentration of polymer in the microspheres, amount 
of crosslinking agent and time of crosslinking affect the in vitro 
mucoadhesion. It was concluded that as the concentration of 
polymer increased, the in vitro mucoadhesion was also increased. It 
was concluded that at the time of crosslinking and the volume of 
crosslinking agent increases, particle size decreases and the 
mucoadhesive strength increases. 
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